Last month, the Lancet, one of the most reputed journals in the world, published the outcomes of the phase III of the clinical trials of Sputnik V. The trial results show a consistent strong protective effect across all participant age groups.
Also known as Gam-COVID-Vac, the vaccine uses a heterologous recombinant adenovirus approach using adenovirus 26 (Ad26) and adenovirus 5 (Ad5) as vectors for the expression of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike protein. The use of two varying serotypes, which are given 21 days apart, is intended to overcome any pre-existing adenovirus immunity in the population. Among the major COVID vaccines in development to date, only Gam-COVID-Vac uses this approach.
Sputnik V has demonstrated an efficacy rate of 91.6 per cent in the interim analysis of the Phase 3 clinical trials, which included data on 19,866 volunteers in Russia, who received both the first and second dose of the vaccine.
"The Phase 3 ongoing trial of Sputnik V may turn into a landmark in untiring journey of COVID Vaccination. It could be possible after partnership between Dr Reddy's Laboratories and Russian agencies. Sputnik V is being commercialized globally by Russian Direct Investment Fund (RDIF). RDIF had in September signed a pact with Dr Reddy's, wherein the Indian drug maker would conduct the bridging study and distribute doses to 100 million people if it were granted a license. This was later increased to 125 million," says Dr. Gajendra Singh, Public Health Expert.
"The recently approved COVID 19 vaccine in India, AstraZeneca has reported 62.1 per cent efficacy as per phase III clinical trial results published by the company in the Lancet in December, while Pfizer and Sputnik V approved in world reportedly has more than 90 per cent efficacy against the virus. Sputnik V can be stored at between two and eight degrees Celsius (between 35.6- and 46.4-degrees Fahrenheit), instead of the temperatures far below freezing required for some other vaccines. As of now, Sputnik V and Pfizer had proven their efficacy to be 90+% while Oxford-AstraZeneca is standing on 62.1% as per their own paper that was submitted to the Lancet magazine. Interestingly, Drugs Controller General of India (DCGI) mentions that AstraZeneca shows average 70% effectiveness in preventing the COVID-19. This is the average/mean efficacy between the regular group that were injected two full doses- 62 per cent and half a dose and full dose- 90 percent. Important to note that India would go for a full-dose regimen. So clearly, there is a lack of transparency here and there should be an informed decision keeping all the aspects in mind," added Dr. Gajendra Singh.
Moreover, vaccines such as Covishield and Sputnik V are fit for Indian terrain since they can be stored between +2 degrees and +8 degrees in contrast with the mRNA vaccines which require extreme temperature regimen of -70º-20ºC for storage.
Interestingly, Sputnik V vaccine has already been approved by several countries across North and South America, the Middle East, Europe, Asia and Africa, the recent ones being Mexico and Egypt. With this, it is now approved for use in more than 35 countries making it one of the world's top three coronavirus vaccines in terms of the number of approvals issued by the regulatory authorities.
In the fight against a virus that brought the world to a standstill, it would be important to collectively find a conducive solution to reach the end point. India not only needs to continue the fight against the pandemic but also win it along with other countries of the world by adopting a pragmatic approach and think beyond nationalism.
(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)
Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.
We, however, have a request.
As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.
Support quality journalism and subscribe to Business Standard.